Insmed Incorporated to Present at Two Investor Conferences in September.
ByAinvest
Thursday, Aug 21, 2025 7:37 am ET1min read
INSM--
Insmed Incorporated is dedicated to delivering first- and best-in-class therapies to transform the lives of patients facing serious diseases. The company's portfolio includes approved and mid- to late-stage investigational medicines, as well as cutting-edge drug discovery focused on serving patient communities with the greatest need. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including two approved therapies for chronic, debilitating lung diseases [2].
The company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Insmed is headquartered in Bridgewater, New Jersey, with offices and research locations throughout the United States, Europe, and Japan [3].
Investors and media interested in attending the presentations can visit the company's investor relations section on its website for more information. The webcasts will be archived for 30 days following the conclusion of the live events.
References:
[1] https://www.prnewswire.com/news-releases/insmed-to-present-at-september-investor-conferences-302535055.html
[2] https://finance.yahoo.com/news/insmed-present-september-investor-conferences-110000193.html
[3] https://www.marketscreener.com/news/insmed-to-present-at-september-investor-conferences-ce7c51d3df88ff27
Insmed Incorporated announced that management will present at the Wells Fargo 2025 Healthcare Conference in Boston on September 5, 2025, and the Morgan Stanley 23rd Annual Global Healthcare Conference in New York on September 9, 2025. The events will be webcast live and available on the company's website. Insmed Incorporated is a biopharmaceutical company focused on delivering therapies for serious diseases.
Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company, has announced that its management will present at two prominent investor conferences in September. The company will participate in the Wells Fargo 2025 Healthcare Conference in Boston on Friday, September 5, 2025, at 8:00 a.m. ET, and the Morgan Stanley 23rd Annual Global Healthcare Conference in New York on Tuesday, September 9, 2025, at 4:50 p.m. ET. Both events will be webcast live and accessible via the company's investor relations section on its website [1].Insmed Incorporated is dedicated to delivering first- and best-in-class therapies to transform the lives of patients facing serious diseases. The company's portfolio includes approved and mid- to late-stage investigational medicines, as well as cutting-edge drug discovery focused on serving patient communities with the greatest need. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including two approved therapies for chronic, debilitating lung diseases [2].
The company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Insmed is headquartered in Bridgewater, New Jersey, with offices and research locations throughout the United States, Europe, and Japan [3].
Investors and media interested in attending the presentations can visit the company's investor relations section on its website for more information. The webcasts will be archived for 30 days following the conclusion of the live events.
References:
[1] https://www.prnewswire.com/news-releases/insmed-to-present-at-september-investor-conferences-302535055.html
[2] https://finance.yahoo.com/news/insmed-present-september-investor-conferences-110000193.html
[3] https://www.marketscreener.com/news/insmed-to-present-at-september-investor-conferences-ce7c51d3df88ff27
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet